ing 11q23 are detected by standard cytogenetics in approxi- features. 5, 11, [14] [15] [16] [17] 
Over the past several years, two molecular abnormalities have been identified which occur in a significant percentage of childhood ALLs and are difficult to identify by standard cytogenetics. The t(12;21)(p13;q22) is a newly recognized Introduction non-random translocation that fuses the chromosome 12 gene ETV6 (TEL) to the chromosome 21 gene AML1, resulting in Approximately 3% of childhood acute lymphoblastic leukeproduction of ETV6-AML1 fusion mRNAs and chimeric promia (ALL) occurs in infants less than 1 year of age.
1 The cliniteins. [18] [19] [20] Although rarely observed cytogenetically, this cal and biological features observed in infants with ALL as abnormality is detected molecularly in 15-25% of childhood well as their treatment outcome differ remarkably from those B-precursor ALL and is associated with good risk clinical feaof older children. 2, 3 Infant ALLs often present with hyperleukotures and an excellent treatment outcome. 19, [21] [22] [23] [24] Another cytosis and display a notably increased frequency of central recurring genetic abnormality in childhood ALL is homonervous system involvement and bulky extramedullary diszygous deletion of one or both of a pair of closely linked and ease.
1-4 A T cell phenotype is much less common in infants related tumor suppressor genes (TSGs) located on the short than in older children. 4 The immunophenotypic features of arm of chromosome 9 (9p21): the cyclin-dependent kinase infant B-precursor ALL differ from the phenotype generally inhibitor genes p16
INK4A
(MTS1) and p15 INK4B (MTS2). [25] [26] [27] In observed in older children as many are CD10-negative and co-express myeloid-associated cell surface antigens such as ALL, these genes are predominantly inactivated by homoin Ͼ95% of cases with ETV6-AML1 fusion. 21, 22 Following completion of these analyses, the membranes were stripped zygous deletion. Hemizygous deletion with point mutation of the retained allele is an uncommon event, leading some to sugand co-hybridized with a 360-bp DNA fragment corresponding to p16 INK4A exon 2 33 (a kind gift of Francesco Lo Coco, gest that co-deletion of both genes is specifically selected for as it provides a powerful growth advantage to the cell. [28] [29] [30] Thus, ETV6-AML1 fusion and homozygous deletion of intensities of control BCR bands were scored as containing homozygous deletions of the corresponding gene. Appropriate p16 INK4A and/or p15 INK4B are two of the most common genetic abnormalities in childhood ALL. As neither can be consistpositive (genomic DNA from a healthy individual) and negative (DNA from cell lines known to contain homozygous ently identified by standard cytogenetics, we undertook a molecular study to determine the incidence of these two genetic p16 INK4A and p15 INK4B gene deletions) controls were included on each blot. abnormalities in infant ALL. Because we were particularly interested in determining the relationship between these abnormalities and HRX gene rearrangements, we analyzed infant ALLs from a large cohort in which HRX gene status has previously been determined and correlated with clinical outResults and discussion come. 11 A major hypothesis that we wished to test was whether ETV6-AML1 fusion might identify a subset of HRX-DNA was available from 69 cases of infant ALL for analysis of the status of the ETV6 gene. Of these 69 cases, 55 were germline infant ALLs with an excellent prognosis which could allow treatment stratification and obviate the need for more previously shown to contain HRX rearrangements and 14 to be HRX-germline. 11 None of the 69 infant ALLs analyzed conintensive therapies in some infants with ALL.
tained ETV6 gene rearrangements or homozygous deletions (representative results are shown in Figure 1 ). To ensure that this failure to detect alterations was not due to technical factors, nine cases of randomly selected standard-risk ALL (as Materials and methods defined by the NCI criteria: age 1.00-9.99 years, presenting white blood count Ͻ50 000 36 ) were analyzed in parallel. Of
Patient specimens
these nine standard-risk childhood ALLs, ETV6 was germline Previously, Rubnitz et al 11 reported the HRX gene status in 96 infants enrolled in one of three consecutive Pediatric Oncology Group (POG) clinical trials. Sufficient DNA and/or frozen leukemic cells for additional molecular analyses was available from a subset of these cases and was used to determine ETV6 (69 cases) and p16 INK4A /p15 INK4B (54 cases) gene status. Additional childhood ALL samples were obtained from the cell bank of the Children's Hospital, Denver, CO. All samples were originally collected as part of POG or institutional clinical trials that had been approved by the Institutional Review Boards of individual institutions.
Molecular analyses
Genomic DNA was isolated using the Puregene Genomic DNA Isolation Kit (Gentra, Research Triangle Park, NC, USA) exactly as suggested by the manufacturer. High molecular weight DNA (5-10 g) was digested with BamHI, size-fractionated by electrophoresis in 0.8% agarose gel and transferred to charged nylon membranes (Zeta Probe, Bio-Rad, Hercules, CA, USA). To determine the presence of ETV6 gene rearrangements, the membranes were hybridized using pre- has been demonstrated to detect ETV6 gene rearrangements These data taken together with that presented herein suggest of these 54 cases contained homozygous deletions of either p16 INK4A or p15 INK4B (representative analyses are shown in that ETV6-AML1 fusion is largely confined to a distinct subset of childhood ALLs. When the current study was undertaken, Figure 2 ). As each blot contained control samples with and without co-deletion of p16 INK4A and p15 INK4B we are confident we hypothesized that ETV6-AML1 fusion might help to identify a subset of HRX-germline infant ALLs with an excellent that no cases with homozygous deletions were missed.
In the current study, no infant ALLs were identified which prognosis, perhaps allowing treatment to be stratified on this basis. ). Furthermore, approximately 20% of the infant ALLs studied were HRXsignificant number of cases with genetic events observed commonly in older children: hyperdiploidy, specific non-random germline and 80% were HRX-rearranged, indicating that our sample was quite representative of the two major currently reciprocal translocations, ETV6-AML1 fusion, or homozygous p16 INK4A and/or p15 INK4B deletions. Thus, it appears incorrect recognized molecular subtypes of infant ALL. Thus, while it is possible that individual infant ALLs may be identified that conceptually to visualize infant ALL as consisting of a biologically unique subset (HRX-rearranged cases) superimposed on contain ETV6 rearrangements or homozygous p16 INK4A and/or p15 INK4B deletions, it is highly unlikely that either of these a baseline incidence of ALL that closely resembles that seen in older children. Rather, the data indicate that infant ALL may genetic abnormalities plays a significant role in the overall pathogenesis of infant ALL.
be composed of two (or more) subsets which are biologically distinct from those observed commonly in older children. A major leukemogenic event, HRX gene fusion, has been identified for one subset. A current challenge is to define the genetic events which underlie the other 20-30% of infant ALLs.
